Madison-based biomedical giant Exact Sciences Corp. said Tuesday that the company generated a revenue of $473.8 million in its fourth quarter, which ended Dec. 31, 2021.

The company also announced a total 2021 revenue amount of $1,761.1 million, which is a 20% increase compared to 2020.

Exact Sciences is known for products like Cologuard, which helps patients screen for colorectal cancers at home, as well as Oncotype DX, a collection of breast, colon and prostate cancer tests that aim to give an accurate picture of a tumor’s biological makeup.

Click here to read the full article.